sCD8 Levels and Response to rIL-2 Therapy in Renal Cell Carcinoma
Author Information
Author(s): A. Martens, R.A.J. Janssen, D.Th. Sleijfer, A.A. Heijn, N.H. Mulder, T.H. The, L. de Leij
Primary Institution: University Hospital Groningen
Hypothesis
Early sCD8 plasma levels during subcutaneous rIL-2 therapy in patients with renal cell carcinoma correlate with response.
Conclusion
Patients with a complete or partial remission showed a significantly stronger initial increase of sCD8 compared to those with stable disease or tumor progression.
Supporting Evidence
- Patients with a complete or partial remission showed a significantly stronger initial increase of sCD8 compared to patients with stable disease or tumor progression.
- The mean concentration of sIL-2R increased 17.2 times from baseline during therapy.
- The study involved 12 patients with metastatic renal cell carcinoma.
Takeaway
This study found that patients with kidney cancer who responded well to a treatment had higher levels of a specific immune marker in their blood.
Methodology
Plasma sIL-2R and sCD8 levels were measured in 12 patients before and during rIL-2 therapy.
Limitations
The study included a small sample size and did not assess long-term effects.
Participant Demographics
12 patients (4 females, 8 males; average age: 59 years, range 42-71) with metastatic renal cell carcinoma.
Statistical Information
P-Value
p<0.01
Confidence Interval
95% c.i. 598-1
Statistical Significance
p<0.01
Want to read the original?
Access the complete publication on the publisher's website